<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637399</url>
  </required_header>
  <id_info>
    <org_study_id>16080305</org_study_id>
    <nct_id>NCT04637399</nct_id>
  </id_info>
  <brief_title>Circadian Misalignment in Inflammatory Bowel Disease</brief_title>
  <official_title>Circadian Misalignment as a Disease Risk Factor in Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to explore the role the sleep/wake cycle (Circadian Rhythm) has on Inflammatory&#xD;
      Bowel Disease. Participants will be asked to attend two clinic visits 14 days apart.&#xD;
      Participants will complete a packet of questionnaires regarding their health and sleep&#xD;
      habits. Over the 14 days between visits participants will be asked to wear a wrist actigraphy&#xD;
      device that will measure their sleep-wake activity along with filling in a sleep diary.&#xD;
      During the visits, participants will have a physical exam on visit 1 and on visit 2&#xD;
      participants will be asked to give blood, stool, and urine samples. Additionally,&#xD;
      participants may also give sigmoid tissue samples during an optional unprepped limited&#xD;
      flexible sigmoidoscopy procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long term goal of this Research proposal is to establish that circadian misalignment is a&#xD;
      factor for disease flare in inflammatory bowel disease (IBD). In order to achieve this goal&#xD;
      this project will focus on two aspects that are critical to address in the management of IBD&#xD;
      - disease course and subclinical inflammation. One of the most challenging aspects of IBD&#xD;
      medical care is that IBD has a very heterogeneous disease course. Some patients will quickly&#xD;
      progress to surgery despite aggressive medical therapy while others have no disease flares on&#xD;
      any medications. In order to address these factors, the investigator will access multiple&#xD;
      factors about each IBD patient to determine what their previous disease course has been&#xD;
      (history), known factors of their disease that are associated with disease course (location,&#xD;
      age of diagnosis, etc), and markers of subclinical inflammation that are established&#xD;
      predictors of disease flare. Our overall hypothesis is that circadian misalignment is an&#xD;
      important factor in the disease course in IBD. To test this hypothesis, the investigator will&#xD;
      conduct a series of experiments in humans to elucidate the role of circadian rhythms in IBD.&#xD;
      In Aim 1, the investigator will test the hypothesis that circadian misalignment is present in&#xD;
      IBD with an aggressive disease course by analyzing circadian rhythms by wrist actigraphy,&#xD;
      urinary melatonin, and chronotype questionnaires. In Aim 2, the investigator will assess&#xD;
      markers of subclinical inflammation in the same subjects from Aim1, and analyze established&#xD;
      predictors of disease flare such as CRP, intestinal permeability, fecal calprotectin, and&#xD;
      mucosal inflammation markers. The goal of this research proposal is to identify whether&#xD;
      circadian misalignment is a factor in disease course in IBD. It is not to determine if IBD&#xD;
      patients have increased circadian misalignment compared to healthy controls, therefore&#xD;
      healthy controls are not used as a comparison group. However, Dr. Burgess and Dr. Levi's labs&#xD;
      do have a large historical cohort of over 100 healthy controls that have completed wrist&#xD;
      actigraphy measurements and chronotype questionnaires that can be used as a comparison if our&#xD;
      hypothesis is proven incorrect.&#xD;
&#xD;
      Experimental Design: Subjects with biopsy proven IBD (N=68) will be recruited, 24 CD (Crohn's&#xD;
      Disease) and 24 UC (Ulcerative Colitis). All subjects will be between 18-70 years old.&#xD;
      Subjects will be recruited from the Rush University GI Clinic. All subjects will complete&#xD;
      questionnaires including IBD demographic history, an IBD quality of life, food timing, sleep&#xD;
      questionnaires - PROMIS and RUSATED, and chronotype questionnaires - Owl and Lark and Munich.&#xD;
      Each subject will be accessed by the PI for exclusion criteria including: 1) Active IBD (HBI&#xD;
      ≥ 5 or Modified HBI ≥5); 2) Major depression (score ≥ 15 or any endorsement of suicidal&#xD;
      intent on the Beck Depression; 3) Sleep apnea (score high risk ≥ 2 or more categories on the&#xD;
      Berlin Questionnaire)(43); 4) Restless leg syndrome (score ≥ 15 on the IRLS Study Group&#xD;
      Rating Scale(44)); 5) Regular use of medications that affect intestinal permeability, and/or&#xD;
      endogenous melatonin including metoclopramide, NSAIDs, beta blocker, psychotropic medication,&#xD;
      hypnotics and exogenous melatonin products during 4 weeks prior to the study; 6) People who&#xD;
      have worked night shifts or crossed more than 2 time zones in the previous month; 7) Any&#xD;
      major organ disease - renal impairment (creatinine&gt;1.2 mg/dL - previous EMR labs must be&#xD;
      within the past 12 months), diabetes (Hgb-A1c &gt; 6.5% - no history of any form of diabetes);&#xD;
      liver disease (LFTs &gt; 1.5x nl - previous EMR labs must be within the past 12 months), or&#xD;
      significant cardiac problems; 8) Inability to sign an informed consent.&#xD;
&#xD;
      Subjects that meet these inclusion/exclusion criteria will be assessed by the PI, who will&#xD;
      perform a physical exam, take a history, and review prior medical testing. Subjects will&#xD;
      matched 1:1 during recruitment so N=12 in both CD and UC with aggressive disease and N=12 in&#xD;
      both CD and UC with nonaggressive disease (See Experimental Design). All subjects will then&#xD;
      have their sleep patterns recorded by wrist actigraphy (30 sec epochs, Actiwatch Spectrum,&#xD;
      Phillips Inc.) for 14 days (±3 days). Wrist actigraphy is a reliable standard means of&#xD;
      assessing sleep-wake activity,(45) and will be used to calculate circadian rhythm by&#xD;
      dichotomy index and r24. During the 14days (±3 days) subjects will also keep a detailed&#xD;
      consensus sleep diary which is a standardized prospective sleep measure.(46) At the end of&#xD;
      the 14 days (±3 days), and a day prior to their visit, all subjects will complete an online&#xD;
      self-administered 24 hour food recall (ASA24) and 24 h urine collection for urinary melatonin&#xD;
      which is also a marker of central circadian rhythm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 22, 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Harvey Bradshaw Activity Index</measure>
    <time_frame>1 Day</time_frame>
    <description>Disease Activity: Score 0-4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck's Depression Index</measure>
    <time_frame>Past Two Weeks from Date of Visit</time_frame>
    <description>Score: 0-14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Restless Leg Syndrome Scale</measure>
    <time_frame>Past Week from Date of Visit</time_frame>
    <description>Score 0-14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Berlin OSA Questionnaire</measure>
    <time_frame>Past 3 Months</time_frame>
    <description>Meet 0-1 Category</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Inflammatory Bowel Disease Questionnaire</measure>
    <time_frame>Past Two Weeks from Date of Visit</time_frame>
    <description>Score: 1-7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Munich Chronotype Questionnaire</measure>
    <time_frame>Past 3 Months</time_frame>
    <description>Typical Sleep and Wake Habits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Owl and Lark Questionnaire</measure>
    <time_frame>Past 3 Months</time_frame>
    <description>Extreme morning type 70-86 Moderately morning type 59-69 Neutral type 42-58 Moderately evening type 31-41 Extreme evening type 16-30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ActiWatch</measure>
    <time_frame>14 Day Period</time_frame>
    <description>Sleep-Wake Activity Wrist Monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food Timing Questionnaire</measure>
    <time_frame>14 Day Period</time_frame>
    <description>Food and Sleep Habit Diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Diary</measure>
    <time_frame>14 Day Period</time_frame>
    <description>Sleep Record</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Samples</measure>
    <time_frame>1 Day</time_frame>
    <description>Volume: First 5 hours, Second 19 hours, 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein</measure>
    <time_frame>10 Weeks +/- 3 Days</time_frame>
    <description>milligrams per deciliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Sided Colon Tissue Samples</measure>
    <time_frame>1 Day</time_frame>
    <description>10 Double Bites with Forceps</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Ulcerative Colitis</arm_group_label>
    <description>Participants diagnoses with Ulcerative Colitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's Disease</arm_group_label>
    <description>Participants diagnosed with Crohn's Disease.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults diagnosed with Ulcerative Colitis or Crohn's Disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of Diagnosis is &lt; 40 years&#xD;
&#xD;
          -  Documented biopsy proven Crohn's Disease or Ulcerative Colitis&#xD;
&#xD;
          -  Willing to sign study consent form&#xD;
&#xD;
          -  At starting and during the study subject is free of prescription and over the counter&#xD;
             medication that can affect melatonin over the past month: over the counter melatonin&#xD;
             formulation, NSAID, alpha blocker, beta blocker, calcium channel blocker,&#xD;
             benzodiazepine, hypnotic, barbiturate, antiepileptic, antidepressant, antipsychotic,&#xD;
             metoclopramide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active IBD flare (HBI≥5)&#xD;
&#xD;
          -  Use of prednisone in the past 4 weeks&#xD;
&#xD;
          -  Other forms of colitis, such as indeterminate colitis&#xD;
&#xD;
          -  Moderate/severe depression or suicidal thoughts&#xD;
&#xD;
          -  Restless leg syndrome&#xD;
&#xD;
          -  Sleep apnea&#xD;
&#xD;
          -  Surgical history of ileostomy or colectomy with ileal pouch&#xD;
&#xD;
          -  Antibiotic use within the last 14 days prior to stool collection&#xD;
&#xD;
          -  Active or recent infection in the last 14 days prior to stool collection&#xD;
&#xD;
          -  Abnormal bleeding parameters (i.e., prolonged INR), history of easy bruising or&#xD;
             bleeding (except rectal bleeding during flare-ups)&#xD;
&#xD;
          -  Psychiatric disorder (diagnosis reported or EMR)&#xD;
&#xD;
          -  Use of anticoagulants and anti-platelet drugs&#xD;
&#xD;
          -  Documented chronic disease (history or current) such as diabetes, lung, heart, eye,&#xD;
             autoimmune, seizures, kidney (creatinine &gt;1.2 mg/dL in last 12 months),or liver&#xD;
             (AST/ALT &gt;1.5x ULN in last 12 months)&#xD;
&#xD;
          -  Night shift work (3 or more nights/week) or more than 2 time zones crossed in past 4&#xD;
             weeks&#xD;
&#xD;
          -  Any children &lt;2 years old living at home&#xD;
&#xD;
          -  WOMEN ONLY: Currently pregnant&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Participating in other research studies involving research interventions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garth Swanson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/25728587</url>
    <description>Randomised clinical trial: Deep remission in biologic and immunomodulator naïve patients with crohn's disease - a SONIC post hoc analysis. - PubMed - NCBI [homepage on the Internet]. [cited 6/9/2016].</description>
  </link>
  <reference>
    <citation>Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008 Dec;135(6):1907-13. doi: 10.1053/j.gastro.2008.09.012. Epub 2008 Sep 17.</citation>
    <PMID>18854185</PMID>
  </reference>
  <reference>
    <citation>Keefer L, Stepanski EJ, Ranjbaran Z, Benson LM, Keshavarzian A. An initial report of sleep disturbance in inactive inflammatory bowel disease. J Clin Sleep Med. 2006 Oct 15;2(4):409-16.</citation>
    <PMID>17557469</PMID>
  </reference>
  <reference>
    <citation>Ali T, Madhoun MF, Orr WC, Rubin DT. Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013 Oct;19(11):2440-3. doi: 10.1097/MIB.0b013e3182a0ea54.</citation>
    <PMID>23945186</PMID>
  </reference>
  <reference>
    <citation>Singh S, Dera AE, Esteban JPG, Chakradeo PS, Lee AA, Burgess HR, Keshavarzian A, Swanson GR. Tu1992 later chronotype is associated with worse quality of life and biologic use in inflammatory bowel disease. Gastroenterology. 2016; 150(4): S999-S1000.</citation>
  </reference>
  <reference>
    <citation>Swanson GR, Gorenz A, Shaikh M, Desai V, Kaminsky T, Van Den Berg J, Murphy T, Raeisi S, Fogg L, Vitaterna MH, Forsyth C, Turek F, Burgess HJ, Keshavarzian A. Night workers with circadian misalignment are susceptible to alcohol-induced intestinal hyperpermeability with social drinking. Am J Physiol Gastrointest Liver Physiol. 2016 Jul 1;311(1):G192-201. doi: 10.1152/ajpgi.00087.2016. Epub 2016 May 19.</citation>
    <PMID>27198191</PMID>
  </reference>
  <reference>
    <citation>Summa KC, Voigt RM, Forsyth CB, Shaikh M, Cavanaugh K, Tang Y, Vitaterna MH, Song S, Turek FW, Keshavarzian A. Disruption of the Circadian Clock in Mice Increases Intestinal Permeability and Promotes Alcohol-Induced Hepatic Pathology and Inflammation. PLoS One. 2013 Jun 18;8(6):e67102. doi: 10.1371/journal.pone.0067102. Print 2013.</citation>
    <PMID>23825629</PMID>
  </reference>
  <reference>
    <citation>Beaugerie L, Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol. 2012 Aug 7;18(29):3806-13. doi: 10.3748/wjg.v18.i29.3806. Review.</citation>
    <PMID>22876031</PMID>
  </reference>
  <reference>
    <citation>Grimstad T, Norheim KB, Isaksen K, Leitao K, Hetta AK, Carlsen A, Karlsen LN, Skoie IM, Gøransson L, Harboe E, Aabakken L, Omdal R. Fatigue in Newly Diagnosed Inflammatory Bowel Disease. J Crohns Colitis. 2015 Sep;9(9):725-30. doi: 10.1093/ecco-jcc/jjv091. Epub 2015 May 19.</citation>
    <PMID>25994356</PMID>
  </reference>
  <reference>
    <citation>Ranjbaran Z, Keefer L, Farhadi A, Stepanski E, Sedghi S, Keshavarzian A. Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol. 2007 Nov;22(11):1748-53.</citation>
    <PMID>17914945</PMID>
  </reference>
  <reference>
    <citation>Shearman LP, Sriram S, Weaver DR, Maywood ES, Chaves I, Zheng B, Kume K, Lee CC, van der Horst GT, Hastings MH, Reppert SM. Interacting molecular loops in the mammalian circadian clock. Science. 2000 May 12;288(5468):1013-9.</citation>
    <PMID>10807566</PMID>
  </reference>
  <reference>
    <citation>Nakahata Y, Yoshida M, Takano A, Soma H, Yamamoto T, Yasuda A, Nakatsu T, Takumi T. A direct repeat of E-box-like elements is required for cell-autonomous circadian rhythm of clock genes. BMC Mol Biol. 2008 Jan 4;9:1. doi: 10.1186/1471-2199-9-1.</citation>
    <PMID>18177499</PMID>
  </reference>
  <reference>
    <citation>Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, Hong HK, Chong JL, Buhr ED, Lee C, Takahashi JS, Imai S, Bass J. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 2009 May 1;324(5927):651-4. doi: 10.1126/science.1171641. Epub 2009 Mar 19.</citation>
    <PMID>19299583</PMID>
  </reference>
  <reference>
    <citation>Laposky AD, Bradley MA, Williams DL, Bass J, Turek FW. Sleep-wake regulation is altered in leptin-resistant (db/db) genetically obese and diabetic mice. Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R2059-66. doi: 10.1152/ajpregu.00026.2008. Epub 2008 Oct 8.</citation>
    <PMID>18843095</PMID>
  </reference>
  <reference>
    <citation>Hoogerwerf WA, Hellmich HL, Cornélissen G, Halberg F, Shahinian VB, Bostwick J, Savidge TC, Cassone VM. Clock gene expression in the murine gastrointestinal tract: endogenous rhythmicity and effects of a feeding regimen. Gastroenterology. 2007 Oct;133(4):1250-60. Epub 2007 Jul 12.</citation>
    <PMID>17919497</PMID>
  </reference>
  <reference>
    <citation>Bozek K, Relógio A, Kielbasa SM, Heine M, Dame C, Kramer A, Herzel H. Regulation of clock-controlled genes in mammals. PLoS One. 2009;4(3):e4882. doi: 10.1371/journal.pone.0004882. Epub 2009 Mar 16.</citation>
    <PMID>19287494</PMID>
  </reference>
  <reference>
    <citation>Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, Schultz PG, Kay SA, Takahashi JS, Hogenesch JB. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 2002 May 3;109(3):307-20.</citation>
    <PMID>12015981</PMID>
  </reference>
  <reference>
    <citation>Turek FW. Circadian clocks: tips from the tip of the iceberg. Nature. 2008 Dec 18;456(7224):881-3. doi: 10.1038/456881a.</citation>
    <PMID>19092918</PMID>
  </reference>
  <reference>
    <citation>Bell-Pedersen D, Cassone VM, Earnest DJ, Golden SS, Hardin PE, Thomas TL, Zoran MJ. Circadian rhythms from multiple oscillators: lessons from diverse organisms. Nat Rev Genet. 2005 Jul;6(7):544-56. Review.</citation>
    <PMID>15951747</PMID>
  </reference>
  <reference>
    <citation>Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, Iino M, Hashimoto S. System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nat Genet. 2005 Feb;37(2):187-92. Epub 2005 Jan 23.</citation>
    <PMID>15665827</PMID>
  </reference>
  <reference>
    <citation>Nojkov B, Rubenstein JH, Chey WD, Hoogerwerf WA. The impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses. Am J Gastroenterol. 2010 Apr;105(4):842-7. doi: 10.1038/ajg.2010.48. Epub 2010 Feb 16.</citation>
    <PMID>20160712</PMID>
  </reference>
  <reference>
    <citation>Brzozowski T, Zwirska-Korczala K, Konturek PC, Konturek SJ, Sliwowski Z, Pawlik M, Kwiecien S, Drozdowicz D, Mazurkiewicz-Janik M, Bielanski W, Pawlik WW. Role of circadian rhythm and endogenous melatonin in pathogenesis of acute gastric bleeding erosions induced by stress. J Physiol Pharmacol. 2007 Dec;58 Suppl 6:53-64.</citation>
    <PMID>18212400</PMID>
  </reference>
  <reference>
    <citation>Kolstad HA. Nightshift work and risk of breast cancer and other cancers--a critical review of the epidemiologic evidence. Scand J Work Environ Health. 2008 Feb;34(1):5-22. Review.</citation>
    <PMID>18427694</PMID>
  </reference>
  <reference>
    <citation>Wong PM, Hasler BP, Kamarck TW, Muldoon MF, Manuck SB. Social Jetlag, Chronotype, and Cardiometabolic Risk. J Clin Endocrinol Metab. 2015 Dec;100(12):4612-20. doi: 10.1210/jc.2015-2923. Epub 2015 Nov 18.</citation>
    <PMID>26580236</PMID>
  </reference>
  <reference>
    <citation>Mazzoccoli G, Palmieri O, Corritore G, Latiano T, Bossa F, Scimeca D, Biscaglia G, Valvano MR, D'Incà R, Cucchiara S, Stronati L, Annese V, Andriulli A, Latiano A. Association study of a polymorphism in clock gene PERIOD3 and risk of inflammatory bowel disease. Chronobiol Int. 2012 Oct;29(8):994-1003. doi: 10.3109/07420528.2012.705935. Epub 2012 Aug 10.</citation>
    <PMID>22881285</PMID>
  </reference>
  <reference>
    <citation>Burgess HJ, Swanson GR, Keshavarzian A. Endogenous melatonin profiles in asymptomatic inflammatory bowel disease. Scand J Gastroenterol. 2010 Jun;45(6):759-61. doi: 10.3109/00365521003749818.</citation>
    <PMID>20345337</PMID>
  </reference>
  <reference>
    <citation>Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb;122(2):512-30. Review.</citation>
    <PMID>11832465</PMID>
  </reference>
  <reference>
    <citation>Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014 Feb;146(2):392-400.e3.</citation>
    <PMID>24512909</PMID>
  </reference>
  <reference>
    <citation>D'Incà R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, Venturi C, Longo G, Sturniolo GC. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol. 1999 Oct;94(10):2956-60.</citation>
    <PMID>10520851</PMID>
  </reference>
  <reference>
    <citation>Wyatt J, Oberhuber G, Pongratz S, Püspök A, Moser G, Novacek G, Lochs H, Vogelsang H. Increased gastric and intestinal permeability in patients with Crohn's disease. Am J Gastroenterol. 1997 Oct;92(10):1891-6.</citation>
    <PMID>9382060</PMID>
  </reference>
  <reference>
    <citation>Swanson G, Forsyth CB, Tang Y, Shaikh M, Zhang L, Turek FW, Keshavarzian A. Role of intestinal circadian genes in alcohol-induced gut leakiness. Alcohol Clin Exp Res. 2011 Jul;35(7):1305-14. doi: 10.1111/j.1530-0277.2011.01466.x. Epub 2011 Apr 4.</citation>
    <PMID>21463335</PMID>
  </reference>
  <reference>
    <citation>Preuss F, Tang Y, Laposky AD, Arble D, Keshavarzian A, Turek FW. Adverse effects of chronic circadian desynchronization in animals in a &quot;challenging&quot; environment. Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R2034-40. doi: 10.1152/ajpregu.00118.2008. Epub 2008 Oct 8.</citation>
    <PMID>18843092</PMID>
  </reference>
  <reference>
    <citation>Natale V, Innominato PF, Boreggiani M, Tonetti L, Filardi M, Parganiha A, Fabbri M, Martoni M, Lévi F. The difference between in bed and out of bed activity as a behavioral marker of cancer patients: A comparative actigraphic study. Chronobiol Int. 2015;32(7):925-33. doi: 10.3109/07420528.2015.1053909.</citation>
    <PMID>26158757</PMID>
  </reference>
  <reference>
    <citation>Lévi F, Dugué PA, Innominato P, Karaboué A, Dispersyn G, Parganiha A, Giacchetti S, Moreau T, Focan C, Waterhouse J, Spiegel D; ARTBC Chronotherapy Group. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiol Int. 2014 Oct;31(8):891-900. doi: 10.3109/07420528.2014.924523. Epub 2014 Jun 13.</citation>
    <PMID>24927369</PMID>
  </reference>
  <reference>
    <citation>Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol. 1999 Jan;94(1):200-7.</citation>
    <PMID>9934756</PMID>
  </reference>
  <reference>
    <citation>Banan A, Choudhary S, Zhang Y, Fields JZ, Keshavarzian A. Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. J Pharmacol Exp Ther. 1999 Dec;291(3):1075-85.</citation>
    <PMID>10565827</PMID>
  </reference>
  <reference>
    <citation>Banan A, Fields JZ, Decker H, Zhang Y, Keshavarzian A. Nitric oxide and its metabolites mediate ethanol-induced microtubule disruption and intestinal barrier dysfunction. J Pharmacol Exp Ther. 2000 Sep;294(3):997-1008.</citation>
    <PMID>10945852</PMID>
  </reference>
  <reference>
    <citation>Burgess HJ, Eastman CI. The dim light melatonin onset following fixed and free sleep schedules. J Sleep Res. 2005 Sep;14(3):229-37.</citation>
    <PMID>16120097</PMID>
  </reference>
  <reference>
    <citation>Burgess HJ, Eastman CI. Early versus late bedtimes phase shift the human dim light melatonin rhythm despite a fixed morning lights on time. Neurosci Lett. 2004 Feb 12;356(2):115-8.</citation>
    <PMID>14746877</PMID>
  </reference>
  <reference>
    <citation>Burgess HJ, Fogg LF. Individual differences in the amount and timing of salivary melatonin secretion. PLoS One. 2008 Aug 26;3(8):e3055. doi: 10.1371/journal.pone.0003055.</citation>
    <PMID>18725972</PMID>
  </reference>
  <reference>
    <citation>Burgess HJ, Eastman CI. Short nights attenuate light-induced circadian phase advances in humans. J Clin Endocrinol Metab. 2005 Aug;90(8):4437-40. Epub 2005 May 10.</citation>
    <PMID>15886231</PMID>
  </reference>
  <reference>
    <citation>Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999 Oct 5;131(7):485-91.</citation>
    <PMID>10507956</PMID>
  </reference>
  <reference>
    <citation>Hening WA, Allen RP. Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med. 2003 Mar;4(2):95-7.</citation>
    <PMID>14592339</PMID>
  </reference>
  <reference>
    <citation>de Souza L, Benedito-Silva AA, Pires ML, Poyares D, Tufik S, Calil HM. Further validation of actigraphy for sleep studies. Sleep. 2003 Feb 1;26(1):81-5.</citation>
    <PMID>12627737</PMID>
  </reference>
  <reference>
    <citation>Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL, Morin CM. The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep. 2012 Feb 1;35(2):287-302. doi: 10.5665/sleep.1642.</citation>
    <PMID>22294820</PMID>
  </reference>
  <reference>
    <citation>Brotherton CS, Martin CA, Long MD, Kappelman MD, Sandler RS. Avoidance of Fiber Is Associated With Greater Risk of Crohn's Disease Flare in a 6-Month Period. Clin Gastroenterol Hepatol. 2016 Aug;14(8):1130-6. doi: 10.1016/j.cgh.2015.12.029. Epub 2015 Dec 31.</citation>
    <PMID>26748217</PMID>
  </reference>
  <reference>
    <citation>Voigt RM, Forsyth CB, Green SJ, Mutlu E, Engen P, Vitaterna MH, Turek FW, Keshavarzian A. Circadian disorganization alters intestinal microbiota. PLoS One. 2014 May 21;9(5):e97500. doi: 10.1371/journal.pone.0097500. eCollection 2014.</citation>
    <PMID>24848969</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04637399/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

